Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026
Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026
Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026
Company Drug PIC

Takeda Wins FDA Approval for MIMRYLO, First‑in‑Class Hepcidin Mimetic for Polycythemia Vera

Fineline Cube Aug 31, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026
Others

Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP‑1 Candidate ASC30

Fineline Cube Aug 31, 2026
Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Fineline Cube Aug 31, 2026

WestGene Biopharma and CREATE Medicines, Inc. announced a strategic license and collaboration agreement combining CREATE’s...

Others

Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP‑1 Candidate ASC30

Fineline Cube Aug 31, 2026

Ascletis Pharma Inc. (HKG: 1672) announced that the first participant has been dosed in the...

Company Deals

Mabwell Licenses SynuSight’s SST001 PET Tracer for α‑Synuclein Imaging in Greater China

Fineline Cube Aug 31, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062; HKG: 2493) announced it has entered into a...

Policy / Regulatory

GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia

Fineline Cube Aug 31, 2026

GluBio Pharmaceuticals announced that GLB‑005, its self‑developed widely interspaced zinc finger (WIZ) molecular glue degrader...

Company Deals PIC

Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103

Fineline Cube Aug 31, 2026

Simnova Biotech announced the completion of a Series B financing round of nearly RMB 400...

Company Deals PIC

Leaderna Therapeutics Closes Series A+ Led by Grand View Capital to Advance Oligonucleotide Pipeline

Fineline Cube Aug 31, 2026

Leaderna Therapeutics announced the completion of its Series A+ financing round, invested exclusively by Grand...

Company Drug PIC

Eli Lilly Wins FDA Approval for Mounjaro Cardiovascular Risk Reduction in Type 2 Diabetes

Fineline Cube Aug 31, 2026

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA)...

Company Drug PIC

Takeda Wins FDA Approval for MIMRYLO, First‑in‑Class Hepcidin Mimetic for Polycythemia Vera

Fineline Cube Aug 31, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that the U.S. Food and Drug...

Company Drug

Fosun Pharma’s Velinotamig Wins NMPA Conditional Approval for Relapsed or Refractory Multiple Myeloma

Fineline Cube Aug 28, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that velinotamig (project code:...

Company Deals

Duality Biologics and Genentech Strike Global ADC Collaboration with USD 1b+ Milestone Potential

Fineline Cube Aug 28, 2026

Duality Biologics (HKG: 9606) announced that it has entered into a global collaboration and license...

Company Drug

HutchMed’s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

Fineline Cube Aug 28, 2026

HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that the New Drug Application (NDA) for...

Company Deals PIC

AusperBio Raises USD 120m Series C to Advance AHB-137 Phase III Trial and Oligonucleotide Pipeline

Fineline Cube Aug 28, 2026

AusperBio announced the completion of a USD 120m Series C financing round, a substantial capital...

Company Drug

Livzon Pharmaceutical’s Lecankitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis

Fineline Cube Aug 28, 2026

Livzon Pharmaceutical (HKG: 1513) announced that lecankitug, jointly developed with Beijing Kanova Biopharma, has been...

Company Drug

TYK Medicines’ Asandeutertinib Wins NMPA Conditional Approval for EGFR-Mutant NSCLC with CNS Metastases

Fineline Cube Aug 28, 2026

TYK Medicines (HKG: 2410) announced that its independently developed next-generation EGFR-TKI, asandeutertinib (TY-9591), has received...

Company Drug

AbbVie Submits EMA Application for SKYRIZI Subcutaneous Induction in Crohn’s Disease

Fineline Cube Aug 28, 2026

AbbVie (NYSE: ABBV) announced that it has submitted an application to the European Medicines Agency...

Company Deals Medical Device PIC

TÜV Rheinland and United Imaging Sign Strategic Cooperation MoU to Accelerate Global Market Access for Medical Devices

Fineline Cube Aug 28, 2026

TÜV Rheinland Greater China and United Imaging Healthcare Co., LTD have signed a strategic cooperation...

Company Deals

ImmuneOnco Doses First Patient in Phase 2 Trial of IMM2510 Combo for First-Line HCC

Fineline Cube Aug 28, 2026

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) announced that the first patient has been dosed in...

Company Medical Device

Asieris Wins EU CE Certification for APLD-2304, the World’s First Portable Single-Use Blue-Light Flexible Cystoscope

Fineline Cube Aug 28, 2026

Jiangsu Asieris Pharmaceuticals Co., Ltd. (SHA: 688176) announced that its APLD-2304 flexible cystoscope has obtained...

Policy / Regulatory

China Health Report: NHC Data Shows Life Expectancy at 79.25 Years as Health Spending Reaches 6.7% of GDP

Fineline Cube Aug 28, 2026

The National Health Commission of China (NHC) released the Statistical Bulletin on Health Development in...

Company Drug PIC

Gilead’s Bixlenvo Wins FDA Approval as Smallest Once-Daily Single Tablet HIV Regimen

Fineline Cube Aug 28, 2026

Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has...

Posts pagination

1 2 … 714

Recent updates

  • WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies
  • Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP‑1 Candidate ASC30
  • Mabwell Licenses SynuSight’s SST001 PET Tracer for α‑Synuclein Imaging in Greater China
  • GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia
  • Simnova Closes nearly RMB 400 Million Series B to Advance CAR‑NK Candidate SNC103
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals PIC

WestGene and CREATE Sign License Deal to Co‑Develop In Vivo CAR‑T Therapies

Others

Ascletis Doses First Patient in Global Phase 3 AURORA Trial of Oral GLP‑1 Candidate ASC30

Company Deals

Mabwell Licenses SynuSight’s SST001 PET Tracer for α‑Synuclein Imaging in Greater China

Policy / Regulatory

GluBio’s GLB‑005 WIZ Degrader Enters NMPA Rare Disease Pilot for β‑Thalassemia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.